Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;60(5):500-3.
doi: 10.1136/jcp.2006.040170. Epub 2006 Jul 5.

Validation of tissue microarray technology in endometrioid cancer of the endometrium

Guus Fons  1 , Siti M Hasibuan, Jacobus van der Velden, Fiebo J W ten Kate
Affiliations

Validation of tissue microarray technology in endometrioid cancer of the endometrium

Guus Fons et al. J Clin Pathol. 2007 May.

Abstract

Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis.

Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the kappa statistic.

Results: Concordance between the staining results of TMA and whole slides was good for PR (kappa = 0.69), oestrogen receptor (kappa = 0.78), p53 (kappa = 0.81) and EMA (kappa = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns.

Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M J, Sauter G, Kallioniemi O P. Tissue microarrays for high‐throughput molecular profiling of tumor specimens. Nat Med 19984844–847. - PubMed
    1. Camp R L, Charette L A, Rimm D L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000801943–1949. - PubMed
    1. Dawson B, Trapp R G.Basic and Clinical Biostatistics. New York: Lange Medical Books/McGraw‐Hill, 2004
    1. Gulmann C, Butler D, Kay E, Grace A, Leader M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 20034270–76. - PubMed
    1. Nocito A, Bubendorf L, Maria T E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger A G, Flury R, Jager P, Luc F J, Schraml P, Moch H, Mihatsch M J, Gasser T, Sauter G. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001194349–357. - PubMed

Publication types

MeSH terms